Results 41 to 50 of about 115,541 (278)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]

, 2018
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto, Campana, Davide, Di Giacinto, Paola, Isidori, Andrea, Lania, Andrea, Lenzi, Andrea, Rizza, Laura, Rota, Francesca, Zuppi, Paolo   +8 more
core   +1 more source

FGFR2 amplification in colorectal adenocarcinoma [PDF]

, 2017
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen.
Carter, Jamal H, Cottrell, Catherine E, Duncavage, Eric J, Heusel, Jonathan W, Lamp, Stephen, McNulty, Samantha N, Vigh-Conrad, Katinka A   +6 more
core   +2 more sources

Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female

Case Reports in Pediatrics, 2016
Endobronchial carcinoid tumors are the most common intrabronchial tumors in children and adolescents. Common signs and symptoms include persistent cough and wheezing not responsive to bronchodilators, hemoptysis, and recurrent fever.
Jonathan D. Cogen, Jonathan Swanson, Thida Ong   +2 more
doaj   +1 more source

Carcinoid tumor of the kidney: An unusual renal tumor

Indian Journal of Urology, 2009
Carcinoid tumors are low-grade malignant tumors that arise from neuroendocrine cells. Primary renal carcinoid is extremely rare. We present a case of 57-year-old male with primary renal carcinoid tumor.
P P Singh, Amit Singh Malhotra, Vikas Kashyap   +2 more
doaj   +1 more source

Transanal minimally invasive surgery for rectal lesions [PDF]

, 2016
Background and Objectives: Transanal minimally invasive surgery (TAMIS) has emerged as an alternative to transanal endoscopic microsurgery (TEM). The authors report their experience with TAMIS for the treatment of mid and high rectal tumors.
Balla, Andrea, Di Lorenzo, Nicola, Franceschilli, Luana, Iafrate, Corrado, La Torre, Marco, Quaresima, Silvia, Shalaby, Mostafa, Sileri, Pierpaolo   +7 more
core   +1 more source

Delayed Recurrence of Atypical Pulmonary Carcinoid Cluster: A Rare Occurrence

Case Reports in Pulmonology, 2014
Carcinoid is one of the most common tumors of the gastrointestinal tract followed by the tracheobronchial tree. Bronchial carcinoid compromises 20% of total carcinoid and accounts for 1–5% of pulmonary malignancies.
Salim Surani, Jennifer Tan, Alexandra Ahumada, Saherish S. Surani, Sivakumar Sudhakaran, Joseph Varon   +5 more
doaj   +1 more source

Late-stage diagnosis of carcinoid heart disease due to lack of access to health care

Cardio-Oncology, 2023
Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022).
Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui, Prince Otchere   +6 more
doaj   +1 more source

Metabolic Signatures of Lung Cancer in Biofluids: NMR-Based Metabonomics of Blood Plasma [PDF]

, 2011
In this work, the variations in the metabolic profile of blood plasma from lung cancer patients and healthy controls were investigated through NMR-based metabonomics, to assess the potential of this approach for lung cancer screening and diagnosis.
Ana Gomes, Ana M. Gil, António S. Barros, Asiago V. M., Bathe O. F., Bell J. D., Brian J. Goodfellow, Brière J.-J., Carrola J., Cláudia M. Rocha, Daykin C. A., Dong J., Duarte I. F., Duarte I. F., Erol A., Fan T. W. M., Fiorenza A. M., Fiorenza A. M., Freedman D. S., Gao H., Gao H. C., Gu H. W., Haffner H. T., Heber D., Iola F. Duarte, Isabel M. Carreira, Joana Carrola, João Bernardo, Jordan K. W., Keun H. C., Kochhar S., Lai H.-S., Laiakis E. C., Lin L., Lina Carvalho, Liu M., Lokhov P. G., Ludwig C., Ma Y., MacIntyre D. A., Maeda J., Muntoni S., Naini A. B., Norton J. A., Okamoto N., Pirozynski M., Psychogios N., Qiu Y. P., Ritchie S. A., Rocha C. M., Sitter B., Spratlin J. L., Sreekumar A., Stringer K. A., Thysell E., Tiziani S., Travis W. D., Trygg J., Urayama S., Vitor Sousa, Xu Q. S., Xue R., Yin P., Zhang J. A., Zhang Z. Y., Zhou J., Zira A. N.   +66 more
core   +2 more sources

Simultaneous surgical treatment of primary ovarian carcinoid and carcinoid heart disease

Polish Journal of Thoracic and Cardiovascular Surgery, 2022
The incidence of neuroendocrine tumors (NET) is 2.5–5 per 100 000 population. Up to 20% of patients with NET develop carcinoid syndrome (CS), and in 40–50% of those carcinoid heart disease (CHD) is reported (0.27 per 100 000 population per year) [1 ...
Uladzimir Andrushchuk, Aliaxandr Saevich, Viktoria Ermochenko, Mikalai Shchatsinka   +3 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source